Category: Nordisk
-
Novo Nordisk has mitigation plans to minimize disruption from port strikes, CNBC reports By Reuters
•
(Reuters) – Danish drugmaker Novo Nordisk (NYSE:) has mitigation plans to reduce or prevent any interruptions in its production due to U.S. seaport strikes, CNBC reported on Tuesday, citing a company spokesperson. The report added that the famous pharmaceutical manufacturers, Wegovy and Ozempic, are planning to ship their products to…
-
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy By Reuters
•
(Reuters) – Novo Nordisk (NYSE:) CEO Lars Jorgensen has agreed to voluntarily testify at a hearing focusing on U.S. prices for weight-loss drugs Ozempic and Wegovy, the Senate Committee on Health, Education, Labor and Pensions said on Friday. A vote by the US Senate Health Committee, which was scheduled to…
-
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices By Reuters
•
WASHINGTON (Reuters) – The U.S. Senate Health Committee said on Tuesday it will vote this month on whether to subpoena Novo Nordisk (NYSE:) to answer questions about U.S. prices for weight-loss drugs Ozempic and Wegovy, which are much higher than their prices in other countries. . countries. The Senate Committee…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
•
Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly’s stock more than quadrupling and Novo’s stock more than tripling over the past three years. while, Pfizer’s (NYSE: PFE) Fortunes…
-
Denmark’s Novo Nordisk expects 27% sales surge this year but faces price pressure for weight loss drug Wegovy amid Eli Lilly competition
•
Novo Nordisk A/S raised its earnings forecast as the drugmaker now ships five times more introductory doses of the weight-loss drug Wegovy in the US than at the end of last year. More than 25,000 patients are now starting treatment each week in the United States, CEO Lars Frørgaard Jørgensen…